Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
- Category: Small Molecules
- Published on Friday, 10 November 2017 16:56
- Hits: 606
- Data Support the Selection of the Recommended Daily Dose of 150 mg -
- Durable Disease Control Rates in Heavily Pretreated GIST Patients and Reductions in KIT Mutations Supporting pan-KIT Activity of DCC-2618 Across Spectrum of Exons -
- DCC-2618 Continues to Demonstrate Good Tolerability with Over 120 Patients Dosed to Date -
WALTHAM, MA, USA I November 10, 2017 I Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the presentation of data analysis from its ongoing Phase 1 clinical trial of DCC-2618, the Company’s pan-KIT and PDGFRα inhibitor. The analysis and update was presented at the Annual Meeting of The Connective Tissue Oncology Society (CTOS) on November 10, 2017, in Maui, HI, USA. The presentation reviews data from the same trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in September 2017, and provides pharmacodynamic support for the recommended dose of 150 mg once daily. As reported at ESMO, the data showed that in heavily pretreated patients with gastrointestinal stromal tumors (GIST), treatment with DCC-2618 at >100 mg daily resulted in disease control rates of 76% at 12 weeks and 57% at 24 weeks.
Deciphera also provided an update on enrollment of the ongoing Phase 1 clinical trial announcing that as of October 31, 2017, a total of 125 patients had been dosed with DCC-2618 of which 109 were GIST patients, including 54 GIST patients in three expansion cohorts of the Phase 1 trial, which are enrolling 2nd-line, 3rd-line, and fourth-to-fifth line GIST patients, respectively.
“The analysis presented at CTOS supports the selection of 150 mg once daily as the recommend dose and supports the planned evaluation of DCC-2618 in a placebo-controlled, randomized, pivotal Phase 3 trial in patients with GIST, who have previously failed all three approved therapies,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals. “There are no approved therapies for these fourth-line GIST patients and new treatment options are desperately needed.”
“The clinical profile of DCC-2618 continues to demonstrate good tolerability and durable responses in GIST patients who were resistant to other kinase inhibitors,” said Oliver Rosen, M.D., Chief Medical Officer of Deciphera Pharmaceuticals. “The extent of the reductions in KIT mutant allele frequencies observed at doses as low as 100 mg daily across the spectrum of exons 9, 11, 13, 14, 17 and 18 mutations both supports the selection of 150 mg once daily as the recommend dose and provides clinical evidence in these patients of the pan-KIT profile of DCC-2618.”
In an oral presentation, titled “DCC-2618, a novel pan-KIT and PDGFRα kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with gastrointestinal stromal tumor (GIST),” Dr. Neeta Somaiah, M.D., The University of Texas MD Anderson Cancer Center, presented safety data from 70 patients, 57 of which were heavily pretreated GIST patients. As of July 28, 2017, data showed:
- DCC-2618 was generally well-tolerated at all dose levels studied with three dose limiting toxicity events determined to be not clinically significant (two Grade 3 lipase elevations and one Grade 4 CPK elevation).
- At daily doses of 100 mg or greater, GIST patients with KIT or PDGFRα driven disease on DCC-2618 showed a disease control rate (DCR) of 76% at 12 weeks (n=25) and a DCR of 57% at 24 weeks (n=21). DCR is defined as patients with stable disease, partial response or complete response as assessed by Response Evaluation Criteria in Solid Tumors, or RECIST.
- Treatment with DCC-2618 resulted in reductions in cfDNA KIT mutant allele frequencies (MAF) compared to baseline values (n=19) at doses as low as 100 mg daily supporting the selection of 150 mg once daily as the recommended dose and supporting the pan-KIT profile of DCC-2618.
DCC-2618 is currently in a first-in-human Phase 1 clinical trial. DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
SOURCE: Deciphera Pharmaceuticals